ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma

• Published in: Journal of clinical oncology Vol. 35; no. 15_suppl; p. TPS8582
• Main Authors: Szlosarek, Peter Wojciech, Baas, Paul, Ceresoli, Giovanni Luca, Fennell, Dean Anthony, Gilligan, David, Johnston, Amanda, Lee, Phuong, Mansfield, Aaron Scott, Nolan, Luke, Nowak, Anna K., Steele, Jeremy P. C., Taylor, Paul, Tsao, Anne S., Zauderer, Marjorie Glass, Bomalaski, John S.
• Format: Journal Article
• Language: English
• Published: 20.05.2017

Abstract only TPS8582 Background: Argininosuccinate synthetase 1 (ASS1)-deficient malignant pleural mesothelioma (MPM) is sensitive to arginine deprivation therapy with pegylated arginine deiminase (ADI-PEG20), which also enhances the cytotoxicity of pemetrexed. The TRAP Phase 1 trial (NCT02029690)...